{"id":"W2725925241","doi":"10.1111/bjh.14820","title":"Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab <i>versus</i> chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma","year":2017,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Pfizer","keywords":"Rituximab; Medicine; Calicheamicin; Internal medicine; Oncology; Hazard ratio; Interim analysis; Refractory (planetary science); CD22; Clinical endpoint; Aggressive lymphoma; Lymphoma; CD20; Clinical trial; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001236275,0.001020564,0.009829811,0.0006746379,0.000316927,0.0001541783,0.0009725621,0.002197126,0.0002102499],"category_scores_gemma":[0.001666586,0.0009518191,0.003214247,0.0001235927,0.001102458,0.000296927,0.0001256984,0.001439201,0.00003333462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001520697,"about_ca_system_score_gemma":0.004546788,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006358624,"about_ca_topic_score_gemma":0.00003947219,"domain_scores_codex":[0.9929563,0.0006572921,0.003325375,0.0008758436,0.001126936,0.001058279],"domain_scores_gemma":[0.9848018,0.00281127,0.009792496,0.001045109,0.001222107,0.00032725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4713548,0.004417251,0.000002143077,0.0008347275,0.002345419,0.1146234,0.000185815,9.152641e-7,0.0000170943,0.000007875259,0.3922432,0.01396732],"study_design_scores_gemma":[0.7593104,0.005573008,0.000003376941,0.003322857,0.00402947,0.09210863,0.0000490857,0.00004577607,0.001907001,0.0001531945,0.1329522,0.0005449891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7910817,0.06144106,0.0009505249,0.1123896,0.01567398,0.01354849,0.00173564,0.00009936605,0.003079606],"genre_scores_gemma":[0.742249,0.06250323,0.008830369,0.1483318,0.02574653,0.002095967,0.002767333,0.001292343,0.006183433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2879556,"threshold_uncertainty_score":0.9992932,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02536001530919176,"score_gpt":0.3144805966185323,"score_spread":0.2891205813093406,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}